BR112014032555A2 - nalmefeno para a redução do consumo de álcool em populações alvo específicas - Google Patents
nalmefeno para a redução do consumo de álcool em populações alvo específicasInfo
- Publication number
- BR112014032555A2 BR112014032555A2 BR112014032555A BR112014032555A BR112014032555A2 BR 112014032555 A2 BR112014032555 A2 BR 112014032555A2 BR 112014032555 A BR112014032555 A BR 112014032555A BR 112014032555 A BR112014032555 A BR 112014032555A BR 112014032555 A2 BR112014032555 A2 BR 112014032555A2
- Authority
- BR
- Brazil
- Prior art keywords
- nalmefene
- alcohol consumption
- reducing alcohol
- specific target
- target populations
- Prior art date
Links
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title abstract 6
- WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 title abstract 4
- 229960005297 nalmefene Drugs 0.000 title abstract 4
- 230000001419 dependent effect Effects 0.000 abstract 2
- 230000035622 drinking Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261664804P | 2012-06-27 | 2012-06-27 | |
| US201261721539P | 2012-11-02 | 2012-11-02 | |
| US201261736740P | 2012-12-13 | 2012-12-13 | |
| US201361788810P | 2013-03-15 | 2013-03-15 | |
| PCT/EP2013/063461 WO2014001427A1 (en) | 2012-06-27 | 2013-06-27 | Nalmefene for reduction of alcohol consumption in specific target populations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014032555A2 true BR112014032555A2 (pt) | 2017-06-27 |
Family
ID=48703496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014032555A BR112014032555A2 (pt) | 2012-06-27 | 2013-06-27 | nalmefeno para a redução do consumo de álcool em populações alvo específicas |
Country Status (35)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140005217A1 (en) | 2012-06-27 | 2014-01-02 | H. Lundbeck A/S | Nalmefene for reduction of alcohol consumption in specific target populations |
| WO2014170353A1 (en) * | 2013-04-17 | 2014-10-23 | H. Lundbeck A/S | Nalmefene for treatment of patients with sleep disorder |
| EP3134090B1 (en) | 2014-04-22 | 2019-06-05 | Otsuka Pharmaceutical Co., Ltd. | Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders |
| US20170071590A1 (en) * | 2015-09-10 | 2017-03-16 | Suture Armor Llc | Suture anchor |
| KR102699603B1 (ko) | 2018-04-20 | 2024-08-29 | 삼성전자주식회사 | 반도체 메모리 소자 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3814768A (en) | 1971-11-26 | 1974-06-04 | Lewenstein E | 6-methylene-6-desoxy dihydro morphine and codeine derivatives and pharmaceutically acceptable salts |
| US4535157A (en) | 1983-11-01 | 1985-08-13 | Key Pharmaceuticals, Inc. | Process for making 6-desoxy-6-methylenenaloxone and 6-desoxy-6-methylenenaltrexone |
| US5086058A (en) * | 1990-06-04 | 1992-02-04 | Alko Ltd. | Method for treating alcoholism with nalmefene |
| EP1423116A1 (en) * | 2001-08-14 | 2004-06-02 | Biotie Therapies Corp. | Method of treating alcoholism or alcohol abuse |
| UA102128C2 (en) * | 2008-12-05 | 2013-06-10 | Х. Луннбек А/С | Nalmefene hydrochloride dihydrate |
| ES2564006T3 (es) | 2009-05-25 | 2016-03-17 | H. Lundbeck A/S | Preparación de hidrocloruro de nalmefeno a partir de naltrexona |
| SMT201700177T1 (it) | 2010-11-05 | 2017-05-08 | H Lundbeck As | Procedimento per la fabbricazione di naltrexone |
| WO2012134410A1 (en) | 2011-03-31 | 2012-10-04 | Ak Kimya Ithalat-Ihracat Ve Sanayii A.S. | Compositions of opioid antagonists and their use for treating scleroderma |
| US20140005217A1 (en) | 2012-06-27 | 2014-01-02 | H. Lundbeck A/S | Nalmefene for reduction of alcohol consumption in specific target populations |
-
2013
- 2013-06-26 US US13/928,332 patent/US20140005217A1/en not_active Abandoned
- 2013-06-26 US US13/928,317 patent/US20140005216A1/en not_active Abandoned
- 2013-06-27 HU HUE16187426A patent/HUE036272T2/hu unknown
- 2013-06-27 SG SG11201408704WA patent/SG11201408704WA/en unknown
- 2013-06-27 HU HUE23163177A patent/HUE070621T2/hu unknown
- 2013-06-27 HU HUE13732471A patent/HUE031110T2/en unknown
- 2013-06-27 DK DK16187426.8T patent/DK3138564T3/en active
- 2013-06-27 FI FIEP17206034.5T patent/FI3345604T3/fi active
- 2013-06-27 RS RS20161173A patent/RS55456B1/sr unknown
- 2013-06-27 KR KR1020147035322A patent/KR20150023396A/ko not_active Abandoned
- 2013-06-27 WO PCT/EP2013/063461 patent/WO2014001427A1/en not_active Ceased
- 2013-06-27 CN CN201380034056.2A patent/CN104411313A/zh active Pending
- 2013-06-27 PT PT137324711T patent/PT2866808T/pt unknown
- 2013-06-27 SM SM20160471T patent/SMT201600471T1/it unknown
- 2013-06-27 PT PT172060345T patent/PT3345604T/pt unknown
- 2013-06-27 EA EA201492152A patent/EA029908B1/ru not_active IP Right Cessation
- 2013-06-27 ME MEP-2016-286A patent/ME02587B/me unknown
- 2013-06-27 LT LTEP13732471.1T patent/LT2866808T/lt unknown
- 2013-06-27 EP EP13732471.1A patent/EP2866808B1/en not_active Revoked
- 2013-06-27 DK DK17206034.5T patent/DK3345604T3/da active
- 2013-06-27 PL PL23163177.1T patent/PL4223296T3/pl unknown
- 2013-06-27 RS RS20180359A patent/RS57046B1/sr unknown
- 2013-06-27 CA CA2874703A patent/CA2874703C/en active Active
- 2013-06-27 PL PL13732471T patent/PL2866808T3/pl unknown
- 2013-06-27 ES ES16187426.8T patent/ES2663532T3/es active Active
- 2013-06-27 HR HRP20161717TT patent/HRP20161717T1/hr unknown
- 2013-06-27 PL PL16187426T patent/PL3138564T3/pl unknown
- 2013-06-27 EP EP17206034.5A patent/EP3345604B1/en active Active
- 2013-06-27 SM SM20180164T patent/SMT201800164T1/it unknown
- 2013-06-27 HR HRP20230762TT patent/HRP20230762T8/hr unknown
- 2013-06-27 NZ NZ702191A patent/NZ702191A/en not_active IP Right Cessation
- 2013-06-27 JP JP2015519085A patent/JP6258933B2/ja active Active
- 2013-06-27 ME MEP-2018-68A patent/ME03030B/me unknown
- 2013-06-27 LT LTEP17206034.5T patent/LT3345604T/lt unknown
- 2013-06-27 PT PT161874268T patent/PT3138564T/pt unknown
- 2013-06-27 SI SI201330973T patent/SI3138564T1/en unknown
- 2013-06-27 EP EP24221142.3A patent/EP4541421A3/en active Pending
- 2013-06-27 MY MYPI2014003570A patent/MY166914A/en unknown
- 2013-06-27 ES ES23163177T patent/ES3014068T3/es active Active
- 2013-06-27 ES ES13732471.1T patent/ES2609122T3/es active Active
- 2013-06-27 HR HRP20250329TT patent/HRP20250329T1/hr unknown
- 2013-06-27 ES ES17206034T patent/ES2950492T3/es active Active
- 2013-06-27 PL PL17206034.5T patent/PL3345604T3/pl unknown
- 2013-06-27 AU AU2013283281A patent/AU2013283281B2/en not_active Ceased
- 2013-06-27 EP EP16187426.8A patent/EP3138564B1/en not_active Revoked
- 2013-06-27 LT LTEP16187426.8T patent/LT3138564T/lt unknown
- 2013-06-27 BR BR112014032555A patent/BR112014032555A2/pt not_active Application Discontinuation
- 2013-06-27 HU HUE17206034A patent/HUE063313T2/hu unknown
- 2013-06-27 SI SI201330449A patent/SI2866808T1/sl unknown
- 2013-06-27 UA UAA201500199A patent/UA114199C2/uk unknown
- 2013-06-27 MX MX2014015488A patent/MX371373B/es active IP Right Grant
- 2013-06-27 DK DK13732471.1T patent/DK2866808T3/en active
- 2013-06-27 EP EP23163177.1A patent/EP4223296B1/en active Active
- 2013-06-27 RU RU2014151156A patent/RU2665373C2/ru active
- 2013-06-27 SI SI201332054T patent/SI3345604T1/sl unknown
-
2014
- 2014-12-02 IL IL236035A patent/IL236035B/en active IP Right Grant
- 2014-12-15 PH PH12014502798A patent/PH12014502798A1/en unknown
- 2014-12-22 CO CO14280546A patent/CO7160087A2/es not_active Application Discontinuation
- 2014-12-22 CL CL2014003484A patent/CL2014003484A1/es unknown
- 2014-12-23 ZA ZA2014/09525A patent/ZA201409525B/en unknown
-
2016
- 2016-04-07 US US15/093,097 patent/US9642849B2/en active Active
- 2016-12-27 SM SM201600471T patent/SMT201600471B/it unknown
-
2017
- 2017-01-03 CY CY20171100004T patent/CY1118579T1/el unknown
- 2017-03-22 US US15/466,024 patent/US10034874B2/en active Active
- 2017-09-22 JP JP2017182608A patent/JP2018039810A/ja not_active Withdrawn
-
2018
- 2018-02-28 HR HRP20180363TT patent/HRP20180363T1/hr unknown
- 2018-03-27 CY CY20181100346T patent/CY1120097T1/el unknown
- 2018-11-20 HK HK18114830.5A patent/HK1255683A1/en unknown
-
2019
- 2019-04-25 JP JP2019083718A patent/JP6857684B2/ja active Active
-
2023
- 2023-07-25 CY CY20231100359T patent/CY1126140T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2014000314A1 (es) | Compuestos derivados de ciclopropanamina, inhibidores de desmetilasa especifica de lisina 1 (lsd1); medicamento que los comprende; metodo para profilaxis o tratamiento; metodo para inhibir lsd1; y su uso en la profilaxis o tratamiento de esquizofrenia, enfermedad de alzheimer, enfermedad de parkinson o corea de huntington. | |
| BR112013031713A2 (pt) | núcleo absorvente para artigos absorventes descartáveis | |
| AR088083A1 (es) | USO DE ANTICUERPOS DE UNION A IL-1b | |
| DOP2013000300A (es) | Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos | |
| BR112013025777A2 (pt) | imidazopiridazinas como inibidores da quinase akt | |
| BR112015002372A2 (pt) | composições e métodos para a redução do teor de álcool no sangue | |
| ECSP13012520A (es) | Proceso para la preparación de inhibidores de pan-cdk de la fórmula (i), e intermediarios de la preparación | |
| CR20150390A (es) | Inhibidores de la yodoproteina basada en 2,3-dihidroimidazol[1,2-c]pirimidin-5(1-h)-ona-asociada a la fosfolipasa a2 (lp-pla2) | |
| BR112015005691A2 (pt) | transponders de alta temperatura | |
| MX374468B (es) | Composicion farmaceutica acuosa semisolida que contiene tapentadol. | |
| BR112013029026A2 (pt) | filtro para artigos de fumo, arranjo de membros contendo aditivos de artigos de fumo e haste de filtro | |
| BR112014032555A2 (pt) | nalmefeno para a redução do consumo de álcool em populações alvo específicas | |
| BR112015002464B8 (pt) | processo para a preparação de carbamat-benzoxazinona, carbamat-benzoxazinona e uso da carbamat-benzoxazinona | |
| BR112015022513A2 (pt) | produto e método para tratamento de diarreia | |
| BR112015003957A2 (pt) | alfa-1-microglobulina para uso no tratamento de doenças relacionadas com a mitocôndria | |
| BR112013031431A2 (pt) | método para o diagnóstico da doença de gaucher | |
| BR112013026434A2 (pt) | ácidos monocarboxílicos de piperidinila inovadores como agonistas do receptor de s1p1 | |
| BR112015006792A2 (pt) | recipiente tendo indicador de dispensação | |
| BR112014000889A2 (pt) | tratamento para hipoxia | |
| BR112014017587A2 (pt) | métodos e formulações para o tratamento de deficiências de ácido siálico | |
| BR112013000506A2 (pt) | núcleo absorvente | |
| BR112012033437A2 (pt) | núcleo absorvente | |
| BR112017027304A2 (pt) | método para o diagnóstico de doença de farber | |
| BR112014002712A2 (pt) | método para tratamento da esquizofrenia | |
| BR112013030725A2 (pt) | composição |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |